WO2020070540A1 - Methods and compounds for treating diabetes - Google Patents
Methods and compounds for treating diabetesInfo
- Publication number
- WO2020070540A1 WO2020070540A1 PCT/IB2018/057643 IB2018057643W WO2020070540A1 WO 2020070540 A1 WO2020070540 A1 WO 2020070540A1 IB 2018057643 W IB2018057643 W IB 2018057643W WO 2020070540 A1 WO2020070540 A1 WO 2020070540A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- patient
- proteins
- seq
- amino acid
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 116
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 89
- 150000001875 compounds Chemical class 0.000 title abstract description 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 142
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 142
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 35
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 82
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 68
- 239000008194 pharmaceutical composition Substances 0.000 claims description 67
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 64
- 239000008103 glucose Substances 0.000 claims description 59
- 210000004369 blood Anatomy 0.000 claims description 56
- 239000008280 blood Substances 0.000 claims description 56
- 102000004877 Insulin Human genes 0.000 claims description 41
- 108090001061 Insulin Proteins 0.000 claims description 41
- 229940125396 insulin Drugs 0.000 claims description 41
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 30
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 30
- 238000007681 bariatric surgery Methods 0.000 claims description 30
- 230000002159 abnormal effect Effects 0.000 claims description 28
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 28
- 206010022489 Insulin Resistance Diseases 0.000 claims description 16
- 102000017011 Glycated Hemoglobin A Human genes 0.000 claims description 13
- 108010014663 Glycated Hemoglobin A Proteins 0.000 claims description 13
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 12
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 12
- 201000008980 hyperinsulinism Diseases 0.000 claims description 12
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims 4
- 229940123169 Caspase inhibitor Drugs 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 101150002416 Igf2 gene Proteins 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 235000018102 proteins Nutrition 0.000 description 113
- 241000282887 Suidae Species 0.000 description 35
- 210000002966 serum Anatomy 0.000 description 34
- 108010014173 Factor X Proteins 0.000 description 26
- 229940012426 factor x Drugs 0.000 description 26
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 15
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 230000003914 insulin secretion Effects 0.000 description 12
- 229960001052 streptozocin Drugs 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 238000005341 cation exchange Methods 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 238000005194 fractionation Methods 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 125000000539 amino acid group Chemical group 0.000 description 8
- 210000000540 fraction c Anatomy 0.000 description 8
- -1 proteins Chemical class 0.000 description 7
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000003178 anti-diabetic effect Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000007987 MES buffer Substances 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 239000008121 dextrose Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000004190 glucose uptake Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 210000002196 fr. b Anatomy 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 239000012505 Superdex™ Substances 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940120889 dipyrone Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 208000004104 gestational diabetes Diseases 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 238000007446 glucose tolerance test Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 238000012528 insulin ELISA Methods 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000007685 laparoscopic sleeve gastrectomy Methods 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 208000021255 pancreatic insulinoma Diseases 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- HZTYDQRUAWIZRE-UHFFFAOYSA-N 2-[[2-[[1-[2-(dimethylamino)-1-oxoethyl]-5-methoxy-2,3-dihydroindol-6-yl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl]amino]-6-fluoro-N-methylbenzamide Chemical compound CNC(=O)C1=C(F)C=CC=C1NC1=C2C=CN=C2NC(NC=2C(=CC=3CCN(C=3C=2)C(=O)CN(C)C)OC)=N1 HZTYDQRUAWIZRE-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 208000020446 Cardiac disease Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000003790 Foot Ulcer Diseases 0.000 description 1
- 102000030595 Glucokinase Human genes 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- XDMCWZFLLGVIID-SXPRBRBTSA-N O-(3-O-D-galactosyl-N-acetyl-beta-D-galactosaminyl)-L-serine Chemical compound CC(=O)N[C@H]1[C@H](OC[C@H]([NH3+])C([O-])=O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 XDMCWZFLLGVIID-SXPRBRBTSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000000081 effect on glucose Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000002608 insulinlike Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000012743 protein tagging Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
Definitions
- the disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 2 diabetes) or other disorders.
- the disclosure provides for one or more proteins described herein or compositions containing the one or more proteins.
- compounds or compositions containing one or more proteins selected from SEQ ID NOs: 1 - 444 described herein are administered to a patient in need thereof to treat diabetes or diabetes related disorders.
- Diabetes mellitus commonly referred to as diabetes
- diabetes is a major, worldwide medical problem.
- the incidence of DM is increasing in most of the world populations.
- Diabetes is a group of metabolic diseases in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger. If left untreated, diabetes can cause many
- Acute complications can include diabetic ketoacidosis, non-ketotic hyperosmolar coma, or death.
- Serious long-term complications include heart disease, stroke, chronic kidney failure, foot ulcers, and damage to the eyes.
- Diabetes is due to, for example, the pancreas not producing enough insulin or to the cells of the body not responding properly to the insulin produced.
- Type 1 DM results from the pancreas's failure to produce enough insulin. This form was previously referred to as“insulin-dependent diabetes mellitus” (IDDM) or“juvenile diabetes”. The cause is unknown.
- Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses a lack of insulin may also develop. This form was previously referred to as“non insulin dependent diabetes mellitus” (NIDDM) or“adult-onset diabetes”. The primary cause is excessive body weight and not enough exercise.
- NIDDM non insulin dependent diabetes mellitus
- Gestational diabetes is the third main form and occurs when pregnant women without a previous history of diabetes develop high blood-sugar levels.
- Type 1 DM can be managed with insulin injections.
- Type 2 DM may be treated with medications with or without insulin. Insulin and some oral medications can cause low blood sugar. Gestational diabetes usually resolves after the birth of the baby.
- the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444; and a pharmaceutically acceptable excipient.
- the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs :439-444; and a pharmaceutically acceptable excipient.
- the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs: 1-444; and a pharmaceutically acceptable excipient.
- a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs :439-444; and a pharmaceutically acceptable excipient.
- the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs: 1-444; and a pharmaceutically acceptable excipient.
- the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs :439-444; and a pharmaceutically acceptable excipient.
- the disclosure provides for methods of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1 - 444; and a pharmaceutically acceptable excipient.
- the disclosure provides for methods of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1 - 444, wherein at least one of said one or more proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs:439-444; and a pharmaceutically acceptable excipient.
- the disclosure provides for a method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
- the method comprises administering a pharmaceutical composition including one or more proteins to a patient in need thereof, wherein said one or more proteins are selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444.
- the disclosure provides for a method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
- the method comprises administering a pharmaceutical composition including one or more proteins to a patient in need thereof, wherein said one or more proteins are selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444, and wherein at least one of said one or more proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs:439-444.
- a composition or method described herein comprises only one, only two, only three, only four, or five or more proteins selected from SEQ ID NOs: 1 - 173. In another aspect, a composition or method described herein comprises only one, only two, only three, only four, or five or more proteins selected from SEQ ID NOs: 174 - 444. In another aspect, a composition or method described herein comprises only one, only two, only three, only four, or five or more proteins selected from SEQ ID NOs: 1 - 444.
- an amino acid sequence is at least 98% identical to one of SEQ ID NOs: 1 - 173. In another aspect, an amino acid sequence is at least 98% identical to one of SEQ ID NOs: 174 - 444. In another aspect, an amino acid sequence is at least 98% identical to one of SEQ ID NOs: 1-444.
- an amino acid sequence described herein is at least 99% identical to one of SEQ ID NOs: 1 - 173. In another aspect, an amino acid sequence described herein is at least 99% identical to one of SEQ ID NOs: 174 - 444. In another aspect, an amino acid sequence described herein is at least 99% identical to one of SEQ ID NOs: 1-444.
- a composition or method described herein comprises only one of these proteins. In another aspect, a composition or method described herein comprises only two proteins. In another aspect, a composition or method described herein comprises only three proteins. In another aspect, a composition or method described herein comprises only four proteins. In another aspect, a composition or method described herein comprises five or more proteins.
- composition described herein is administered to a patient who has not undergone bariatric surgery.
- a composition described herein is administered to a patient who exhibits abnormal insulin resistance, blood glucose level, insulin level, glycosylated hemoglobin level, or a combination thereof.
- the disclosure provides for a pharmaceutical composition
- the protein comprising: a protein with an amino acid sequence at least 95% identical to SEQ ID NO 25; and a pharmaceutically acceptable excipient.
- the protein has an amino acid sequence at least 98% identical to SEQ ID NO 25.
- the protein has an amino acid sequence at least 99% identical to SEQ ID NO 25.
- the disclosure provides for methods of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including a protein with an amino acid sequence at least 95% identical to SEQ ID NO 25; and a pharmaceutically acceptable excipient.
- the disclosure provides for a method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof, the method comprising administering a pharmaceutical composition comprising a protein to a patient in need thereof, wherein said protein has an amino acid sequence at least 95% identical to SEQ ID NO 25.
- the protein has an amino acid sequence at least 98% identical to SEQ ID NO 25. In another aspect, the protein has an amino acid sequence at least 99% identical to SEQ ID NO 25.
- composition described herein is administered to a patient who has not undergone bariatric surgery.
- composition described herein is administered to a patient who exhibits abnormal insulin resistance, blood glucose level, insulin level, glycosylated hemoglobin level, or a combination thereof.
- the disclosure provides for a pharmaceutical composition
- a pharmaceutical composition comprising IGF or a variant thereof, and a pharmaceutically acceptable carrier, wherein the IGF or variant thereof is present in an effective amount for treating diabetes.
- the composition is suitable for intravenous administration.
- the disclosure provides for a pharmaceutical composition comprising IGF-2 or a variant thereof, and a pharmaceutically acceptable carrier, wherein the IGF-2 or variant thereof is present in an effective amount for treating diabetes.
- the IGF-2 of this aspect is human.
- the human IGF-2 is recombinant.
- the recombinant human IGF-2 variant is at least 85% identical to IGF-2 (SEQ ID NO: 25).
- the disclosure provides for a method of treating diabetes in a subject who has not undergone bariatric surgery comprising administering to a subject in need thereof an effective amount of IGF or a variant thereof.
- the IGF or variant thereof is IGF-2.
- the IGF-2 is administered by intravenous injection.
- the IGF-2 is administered in a single dose.
- the disclosure provides for a method of treating diabetes comprising administering to a subject in need thereof an effective amount of human IGF-2 or a variant thereof.
- the human IGF-2 is recombinant.
- FIG. 1 depicts the blood glucose levels during an experiment in which RYGB was performed on diabetic pigs.
- FIGs. 2A and 2B depict the blood glucose levels in an experiment in which the full serum was injected to two diabetic piglets, respectively.
- FIG. 3 depicts the separation of the full serum using cation exchange fractionation into three fractions.
- FIG. 4 depicts how the blood glucose levels changed over time in response to injection of each of the fractions identified in FIG. 3.
- FIG. 5 depicts the separation of the full serum using HiLoad Superdex 75 fractionation into four fractions.
- FIG. 6 depicts how the blood glucose levels changed over time in response to injection of each of the fractions identified in FIG. 5.
- FIG. 7 depicts results from beta cell insulin secretion tests performed using the full serum and two fractions thereof.
- FIG. 8 depicts results from beta cell insulin secretion tests performed using active GLP-land fraction C from the cation exchange process.
- FIGS. 9A and 9B depict the blood glucose levels in an experiment in which rhIGF-2 was injected to two diabetic piglets, respectively.
- FIG. 10 shows that rIGF-2 and AH-2 post-operation serum elevate insulin secretion from beta cells in vitro.
- FIG. 11 depicts additional data showing that post-operation pig serum elevates insulin secretion from beta cells in vitro.
- the disclosure provides for biological compounds, such as proteins, as set forth in SEQ ID NOs: 1 - 444.
- Compositions comprising biological compounds described herein and methods of use thereof are also provided.
- the disclosure provides for methods of treating a patient in need thereof with a composition comprising, consisting essentially of, or consisting of SEQ ID NOs: 1 - 444.
- a pharmaceutical composition described herein is administered to a patient who has not undergone bariatric surgery.
- the disclosure further provides for combinations of SEQ ID NOs: 1 - 444 or combinations of proteins described in Table 1.
- combinations of SEQ ID NOs: 1 - 444 can be used in a composition to treat a patient in need thereof, wherein the patient has diabetes, type 2 diabetes, cardiac disease, or any disorder related to obesity.
- the term“bariatric surgery” refers, for example, to Roux-en-Y gastric bypass surgery (often called“gastric bypass”), laparoscopic sleeve gastrectomy (often called“the sleeve” or“gastric sleeve”), adjustable gastric band surgery (often called“the band”), and biliopancreatic diversion with duodenal switch gastric bypass (often abbreviated as “BPD/DS”).
- bariatric surgery is selected from the group consisting of gastric bypass surgery, laparoscopic sleeve gastrectomy, adjustable gastric band surgery, and biliopancreatic diversion with duodenal switch surgery.
- Methods described herein may further comprise reducing at least one of insulin resistance, blood glucose level, obesity, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof in the subject.
- the disclosure provides for reducing at least one of insulin resistance, blood glucose level, obesity, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof by administering a composition or biological compound described herein, for example, one, two, three, four, five, or more proteins selected from SEQ ID NOs: 1 - 173, SEQ ID NOs: 174 - 444, or SEQ ID NOs: 1 - 444.
- the disclosure relates to a method of treating diabetes for example, type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising one or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- a pharmaceutical composition comprising one or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- the patient has not undergone bariatric surgery.
- the composition further comprises a pharmaceutically acceptable excipient or pharmaceutically acceptable salt.
- this disclosure relates to a method of treating diabetes for example, type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and two or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- the patient has not undergone bariatric surgery.
- this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and three or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- the patient has not undergone bariatric surgery.
- this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and four or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- the patient has not undergone bariatric surgery.
- this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only one protein selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery. [0053 ] In another aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only two proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
- this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only three proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- the patient has not undergone bariatric surgery.
- this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only four proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof.
- the patient has not undergone bariatric surgery.
- parenteral e.g., intravenous, intramuscular, intraarterial, intraperitoneal, and the like
- inhalation routes e.g., osmotic pump, and the like.
- compositions contemplated for use in the practice of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting composition contains one or more of the active compounds contemplated for use herein, as active ingredients thereof, in admixture with an organic or inorganic carrier or excipient suitable for nasal, enteral or parenteral applications.
- the active ingredients may be compounded, for example, with the usual non-toxic, pharmaceutically and physiologically acceptable carriers for tablets, pellets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules,
- the carriers that can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form.
- auxiliary, stabilizing, thickening and coloring agents may be used.
- the active compounds contemplated for use herein are included in the pharmaceutical
- composition in an amount sufficient to produce the desired effect upon the target process, condition or disease.
- compositions may contain one or more agents selected from flavoring agents (such as peppermint, oil of wintergreen or cherry), coloring agents, preserving agents, and the like, to provide pharmaceutically elegant and palatable flavoring agents (such as peppermint, oil of wintergreen or cherry), coloring agents, preserving agents, and the like, to provide pharmaceutically elegant and palatable flavoring agents (such as peppermint, oil of wintergreen or cherry), coloring agents, preserving agents, and the like, to provide pharmaceutically elegant and palatable
- Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods.
- the excipients used may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate, sodium phosphate, and the like; (2) granulating and disintegrating agents, such as corn starch, potato starch, alginic acid, and the like; (3) binding agents, such as gum tragacanth, corn starch, gelatin, acacia, and the like; and (4) lubricating agents, such as magnesium stearate, stearic acid, talc, and the like.
- the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate may be employed.
- the tablets may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, incorporated herein by this reference, to form osmotic therapeutic tablets for controlled release.
- the active ingredients may be mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin, or the like. They may also be in the form of soft gelatin capsules wherein the active ingredients are mixed with water or an oil medium, for an example, peanut oil, liquid paraffin, olive oil and the like.
- the pharmaceutical compositions may be in the form of a sterile injectable suspension.
- a suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable excipient, diluent, or solvent, for example, as a solution in l,4-butanediol.
- Sterile, fixed oils are conventionally employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
- sustained release systems including semi-permeable polymer matrices in the form of shaped articles (e.g., films or microcapsules) can also be used for the administration of the active compound employed herein.
- methods for the treatment of a subject having diabetes mellitus comprising administering to said subject an effective amount of a composition comprising metformin and one or more of a bioavailable source of chromium, vanadium, or magnesium, or a
- compositions of the present invention are contemplated as being administered in accordance with the methods disclosed herein.
- diabetes presents a complicated array of conditions and symptoms including abnormal glucose metabolism, insulin resistance, hyperinsulinemia, hyperglycemia, hypertriglyceridemia, elevated LDL, lowered HDL and elevated blood pressure. Because of the interrelatedness of these conditions and symptoms, invention compositions are useful in treating many of them.
- the disclosure provides for isolated or recombinant nucleic acid molecules comprising nucleotide sequences encoding proteins described herein, for example, SEQ ID NOs: 1 - 444.
- the disclosure provides for isolated or recombinant nucleic acid molecules comprising nucleotide sequences encoding proteins described herein, for example, SEQ ID NOs: 1 - 173 or SEQ ID NOs: 174 - 444.
- proteins of the present invention are encoded by a nucleotide sequence.
- the disclosure provides for a nucleotide sequence encoding an amino acid sequence that has at least about 60% about 65%, about 70% about 75%, about 80% about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or greater sequence identity to SEQ ID NOs: 1 - 444.
- proteins of the present invention are encoded by a nucleotide sequence.
- the disclosure provides for a nucleotide sequence encoding an amino acid sequence that has at least about 60% about 65%, about 70% about 75%, about 80% about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or greater sequence identity to SEQ ID NOs: 1 - 173 or SEQ ID NOs: 174 - 444.
- variant isolated nucleic acid molecules can be created by introducing one or more nucleotide substitutions, additions, or deletions into the corresponding nucleotide sequence disclosed herein, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Such variant nucleotide sequences are also encompassed by the present invention.
- conservative amino acid substitutions may be made at one or more, predicted, nonessential amino acid residues.
- A“nonessential” amino acid residue is a residue that can be altered from the wild-type sequence of a protein described herein without altering the biological activity, whereas an“essential” amino acid residue is required for biological activity.
- A“conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
- amino acids with basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine
- nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan
- beta-branched side chains e.g., threonine, valine, isoleucine
- aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
- amino acid substitutions may be made in nonconserved regions that retain function. In general, such substitutions would not be made for conserved amino acid residues, or for amino acid residues residing within a conserved motif, where such residues are essential for protein activity. Examples of residues that are conserved and that may be essential for protein activity include, for example, residues that are identical between all proteins contained in an alignment of similar or related toxins to the sequences of the invention (e.g., residues that are identical in an alignment of homologous proteins).
- residues that are conserved but that may allow conservative amino acid substitutions and still retain activity include, for example, residues that have only conservative substitutions between all proteins contained in an alignment of similar or related toxins to the sequences of the invention (e.g., residues that have only conservative substitutions between all proteins contained in the alignment homologous proteins).
- residues that have only conservative substitutions between all proteins contained in an alignment of similar or related toxins to the sequences of the invention e.g., residues that have only conservative substitutions between all proteins contained in the alignment homologous proteins.
- residues that have only conservative substitutions between all proteins contained in an alignment of similar or related toxins to the sequences of the invention e.g., residues that have only conservative substitutions between all proteins contained in the alignment homologous proteins.
- residues that have only conservative substitutions between all proteins contained in an alignment of similar or related toxins to the sequences of the invention e.g., residues that have only conservative substitutions between all proteins contained in the alignment homologous proteins.
- one of skill in the art
- “Fragments” or“biologically active portions” include protein fragments comprising amino acid sequences sufficiently identical to the amino acid sequence set forth in SEQ ID NOs: 1-444, and that exhibit, for example, anti-diabetic activity.
- variants proteins having an amino acid sequence that is at least about 60%, 65%, about 70%, 75%, about 80%, 85%, about 90%, 91 %, 92%, 93%, 94%,
- Variants include proteins that differ in amino acid sequence due to mutagenesis.
- Variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native protein, that is, retaining anti diabetic activity. In some embodiments, the variants have improved activity relative to the native protein.
- anti-diabetic proteins include amino acid sequences that are shorter than the full-length sequences due to the use of an alternate downstream start site.
- one aspect of the invention concerns antibodies, single-chain antigen binding molecules, or other proteins that specifically bind to one or more of the protein or protein molecules of the invention and their homologs, fusions or fragments.
- the antibody specifically binds to a protein having the amino acid sequence set forth in SEQ ID NOs: 1-444 or a fragment thereof.
- the antibody specifically binds to a fusion protein comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 1-444 or a fragment thereof.
- Antibodies of the invention may be used to quantitatively or qualitatively detect the protein or protein molecules of the invention, or to detect post translational modifications of the proteins.
- an antibody or protein is said to“specifically bind” to a protein or protein molecule of the invention if such binding is not competitively inhibited by the presence of non-related molecules.
- the antibodies of the invention may be contained within a kit useful for detection of the protein or protein molecules of the invention.
- the invention further comprises a method of detecting the protein or protein molecule of the invention (particularly a protein encoded by the amino acid sequence set forth in SEQ ID NOs: 1-444, including variants or fragments thereof that are capable of specifically binding to the antibody of the invention) comprising contacting a sample with the antibody of the invention and determining whether the sample contains the protein or protein molecule of the invention.
- Methods for utilizing antibodies for the detection of a protein or protein of interest are known in the art.
- DNA sequences of a protein may be altered by various methods, and that these alterations may result in DNA sequences encoding proteins with amino acid sequences different than that encoded by a protein of the present invention.
- This protein may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions of one or more amino acids of SEQ ID NOs: 1-444, including up to about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, or more amino acid substitutions, deletions or insertions.
- amino acid sequence variants of a protein can be prepared by mutations in the DNA. This may also be accomplished by one of several forms of mutagenesis and/or in directed evolution. In some aspects, the changes encoded in the amino acid sequence will not substantially affect the function of the protein. Such variants will possess the desired anti-diabetic activity.
- alterations may be made to the protein sequence of many proteins at the amino or carboxy terminus without substantially affecting activity.
- This can include insertions, deletions, or alterations introduced by modem molecular methods, such as PCR, including PCR amplifications that alter or extend the protein coding sequence by inclusion of amino acid encoding sequences in the oligonucleotides utilized in the PCR amplification.
- the protein sequences added can include entire protein-coding sequences, such as those used commonly in the art to generate protein fusions.
- Such fusion proteins are often used to (1) increase expression of a protein of interest (2) introduce a binding domain, enzymatic activity, or epitope to facilitate either protein purification, protein detection, or other experimental uses known in the art (3) target secretion or translation of a protein to a subcellular organelle, such as the periplasmic space of Gram-negative bacteria, or the endoplasmic reticulum of eukaryotic cells, the latter of which often results in glycosylation of the protein.
- a subcellular organelle such as the periplasmic space of Gram-negative bacteria, or the endoplasmic reticulum of eukaryotic cells, the latter of which often results in glycosylation of the protein.
- insulin is the substance that regulates glucose uptake. But in diabetic subjects, insulin no longer performs that role effectively (due to either inadequate levels of insulin or insulin resistance). It has been determined that a substance referred to herein as“factor X” can be used to resolve type II diabetes.
- BLC beta-like cells
- ILM insulin-like material
- the BLC are dormant or inactivated, in which case they do not secrete insulin or ILM or secrete an insufficient amount of insulin or ILM. But after exposure to factor X, the BLC become activated, and will begin to secrete insulin or ILM in response to high levels of glucose.
- One possible mechanism of action is that exposure to factor X causes the BLC to secrete insulin and/or ILM in response to high levels of glucose.
- Another possible mechanism of action is that the BLC are naturally programmed to secrete insulin and/or ILM in response to high levels of glucose, but an unknown substance that deactivates the BLC is ordinarily present. Under this scenario, factor X neutralizes (e.g., switches off) this normally prevailing deactivation substance.
- the BLC will sense the level of glucose in the blood, and will initiate the production of insulin or ILM at levels that correspond to the level of glucose in the blood (so that higher levels of glucose will result in the production of more insulin or ILM).
- This production of insulin or ILM may occur either directly in the BLC themselves or indirectly (e.g. through the action of other cells).
- the insulin or ILM circulates in the blood.
- factor X improves conventional beta cells’ ability to regulate the glucose levels in a subject’s body, or downregulates / turns off another mechanism that prevents the conventional beta cells from properly regulating glucose levels.
- factor X is ordinarily either not present (at least in sufficient quantities) or switched off in diabetic animals that have not undergone RYGB. But bariatric surgery (e.g., RYGB) results in the appearance or upregulation of factor X in the blood of those animals, which ultimately resolves those animals’ diabetes. And most notably, when factor X is obtained from the blood of the post-RYGB animals (whose diabetes has been resolved) and subsequently injected into other diabetic animals (that have not undergone RYGB), the diabetes of the latter animals was also resolved. This indicates that factor X can be used as a non-surgical treatment for diabetes.
- bariatric surgery e.g., RYGB
- factor X is obtained from the blood of the post-RYGB animals (whose diabetes has been resolved) and subsequently injected into other diabetic animals (that have not undergone RYGB)
- the diabetes of the latter animals was also resolved. This indicates that factor X can be used as a non-surgical treatment for diabetes.
- the inventor refers to the substance responsible for the normalization of the glucose levels in these post-RYGB pigs as“factor X” herein. Blood samples were extracted from these post-RYGB pigs for further testing as described below and to isolate factor X, after which the pigs were sacrificed.
- full serum a serum as described below in Appendix B. And after inducing diabetes into a set of piglets using STZ, additional experiments were performed on the diabetic piglets.
- FIGs. 2A and 2B depict the results of one experiment in which the full serum was injected to diabetic piglets.
- the blood glucose level dropped significantly a few days after injection of the full serum, and remained low for the duration of the experiment. This data indicates that factor X was present in the full serum, and that factor X can be used as an injectable treatment for diabetes.
- FIG. 3 depicts the separation of the full serum using cation exchange fractionation on HiTrap SP HP 5 ml column (GE Healthcare) into three fractions labeled A, B, and C. Each of those three fractions was then tested by injecting the respective fraction into diabetic piglets who had not undergone RYGB.
- FIG. 4 depicts how the blood glucose levels changed over time in response to injection of each of these three fractions. A review of this data reveals that fraction C was the most effective in reducing the blood glucose level to the point that the diabetes appears to be resolved, and that the reduction persisted through 17 days after injection. This data indicates that factor X (plus additional proteins) was present in fraction C from the cation exchange process fractionation.
- FIG. 5 depicts the separation of the full serum using a HiLoad Superdex 75 PG (GE Healthcare) gel filtration process into four fractions labeled A, B, C, and D. Each of those four fractions was then tested by injecting the respective fraction into diabetic piglets who had not undergone RYGB.
- FIG. 6 depicts how the blood glucose levels changed over time in response to injection of each of these four fractions. A review of this data reveals that fraction B was the most effective in reducing the blood glucose level to the point that the diabetes appears to be resolved and that the reduction persisted through 17 days after injection. This data indicates that factor X (plus additional proteins) was present in fraction B from the Superdex-75 gel filtration process fractionation.
- Fraction C from the cation exchange process and fraction B from the Superdex-75 gel filtration process are referred to herein as eluate I and eluate II, respectively.
- beta cell insulin secretion tests were performed using the full serum diluted 1 :4, 1 :10, and 1 :20; and using fractions B and C from the cation exchange process, each diluted 1 :4, 1 : 10, and 1 :20.
- FIG. 7 depicts these results, which confirm that fraction C from the cation exchange process was the most effective.
- Beta cell insulin secretion tests were also performed using a control, active GLP-l (a compound known to boost insulin secretion), and fraction C from the cation exchange process.
- FIG. 8 depicts these results, which show that fraction C from the cation exchange process was the most effective.
- a first set of relevant porcine proteins was identified using mass spectrometry from the two active fractions (i.e., fraction C of the cation exchange process and fraction B of the Superdex-75 gel filtration process). And a second set of relevant proteins was identified by finding the human counterparts of the first set of porcine proteins.
- factor X is not ordinarily present (at least in sufficient quantities) to control diabetes in diabetic subjects that have not undergone RYGB or other types of bariatric surgery; and (b) introducing factor X into diabetic subjects is an effective way of obtaining long-lasting control of diabetes in those subjects.
- rhIGF-2 recombinant human IGF-2
- rhIGF-2 recombinant human IGF-2
- rhIGF-2 was injected intravenously into two diabetic pigs, and the effect on glucose levels was monitored. More specifically, a single intravenous injection (500ug) of rhIGF-2 was injected into a 16 kg Delta-4 pig and a 9 kg AH-l pig. The difference in weight of those two pigs corresponded to two different dosages (30 pg/kg and 55 pg/kg) FIGS.
- FIGS. 9A and 9B depict the resulting change in those pigs’ glucose levels over time, and the data in those figures show that hIGF-2 administered to pigs result in glucose levels returning to normal levels (relative to pre-treatment levels). It is important to note that while FIGS. 9A and 9B depict dramatic improvements in the blood glucose levels of two particular pigs, when similar tests were performed on other pigs, the other pigs’ diabetes was not resolved. Further investigation into why the treatment was effective for some of the pigs and not others will be required.
- IGF-2 insulin/IGF receptor family using Tocris GSK1838705 inhibitor (#5111) in vitro. More specifically, testing revealed that adding an IGF receptor inhibitor reduced glucose uptake relative to insulin alone from 7500 to 1300 Em. (540nm) and relative to a post-RYGB serum alone from 15500 to 4500 Em. (540nm), which provides additional evidence that IGF-2 can be responsible for the reduction in glucose in certain circumstances. Similarly, adding an IGF-2 blocking antibody also reduced glucose uptake relative to post-RYGB serum alone from 13500 to 3000 Em. (540nm), which confirms the same point.
- rhIGF-2 was compared to insulin in a glucose uptake assay at concentrations of 10, 100, and 1000 nM.
- the data for the insulin at those three concentrations was 7000, 8000, and 8500 Em. (540nm), respectively; and the data for the rhIGF-2 at those three concentrations was 2000, 4000, and 7600 Em. (540nm), respectively, indicating that high concentrations of rhIGF-2 increases glucose uptake to a similar extent as insulin.
- Transgenic C57BL/6 mouse insulinoma cell line (MIN6) cells originate from a transgenic C57BL/6 mouse insulinoma expressing an insulin-prom oter/T-antigen construct.
- MIN-6 cells express GLUT -2 and glucokinase and respond to glucose within the
- MIN6 cells were plated in 24-well culture plates at 3 c 105 cells/well. After 48 hr, cells were washed twice and preincubated in serum free medium (DMEM 25 mM glucose, 2 mM l-glutamine, and 1 mM sodium pyruvate) for 1 hr. Following pre-incubation step, factor-X induction performed by culturing cells for 3 hr with 500 pl of serum free medium supplemented with 5% post RYGB serum/fractions. Finally, induction medium was replaced with new 500 m ⁇ of serum free medium for 3 hr and collected (stored at -20 °C until assayed) for insulin ELISA analysis (Mercodia Mouse Insulin ELISA #10-1247-01).
- serum free medium DMEM 25 mM glucose, 2 mM l-glutamine, and 1 mM sodium pyruvate
- FIG. 10 shows that rIGF-2 and AH-2 post-operation serum elevate insulin secretion from beta cells in vitro.
- the bars in the second grouping represent beta cells induction with recombinant human IGF-2, and the bars on the right side of the final four groupings represent 3 days post operation serum.
- FIG. 11 contains additional data (from experiment“Delta-6”) showing that delta-6 post-operation pig serum elevates insulin secretion from beta cells in vitro.
- the bars on the right side of each grouping represent three days post operation serum.
- 5% of the pre-operation serum or post-operation serum was diluted in a serum free medium with 3 hr of incubation. Collection of cultured medium for analysis was done using 3 hr incubation with new 0.5 mL serum free medium.
- the respective aspect of the invention provides for a pharmaceutical composition including a protein with an amino acid sequence at least 95% identical to the respective SEQ ID NO and a pharmaceutically acceptable excipient.
- the amino acid sequence of the protein may optionally be at least 98% identical or at least 99% identical to the respective SEQ ID NO.
- Another 444 individual aspects of the invention correspond, respectively, to each of the 444 SEQ ID NOs that appear on tables 1 and 2.
- the respective aspect of the invention provides for a method of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including a protein with an amino acid sequence at least 95% identical to the respective SEQ ID NO and a pharmaceutically acceptable excipient.
- the amino acid sequence of the protein may optionally be at least 98% identical or at least 99% identical to the respective SEQ ID NO.
- Another aspect of the invention provides a pharmaceutical composition according any of the aspects described above for use in the treatment of diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
- Another aspect of the invention provides a pharmaceutical composition according to any of the aspects described above for use as a medicament.
- Another aspect of the invention provides one or more proteins selected from the group consisting of an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to one of SEQ ID NOs: 1-444 for use as a medicament.
- Another aspect of the invention provides one or more proteins selected from the group consisting of an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to one of SEQ ID NOs: 1-444 for use in the treatment of diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
- Another aspect of the invention provides a pharmaceutical composition comprising IGF-2 or a variant thereof for use as a medicament.
- Another aspect of the invention provides a pharmaceutical composition comprising IGF-2 or a variant thereof for use in the treatment of diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
- the pigs are housed individually under standardized conditions (l9-23°C; 40-70% relative humidity; 12: 12 hour day/night cycle).
- the pigs undergo surgery, which consists of an indwelling silicon catheter into the jugular vein under aseptic conditions.
- surgery which consists of an indwelling silicon catheter into the jugular vein under aseptic conditions.
- preoperative intramuscular (I.M) ketamine (20 mg/kg) + xylazine (2 mg/kg) is injected, and then insertion of catheter (Venflon) into the ear vein and injection of midazolam
- I.V intravenously
- the pigs are injected with Ceforal 1 gr I.M and Dipyrone 1 gr I.M.
- the pigs are intubated and general anesthesia maintained with isoflurane vaporized in oxygen.
- the concentration of isoflurane (1 - 2.5%) continuously adjusted to achieve an adequate depth of anesthesia.
- the silicon catheter is inserted into the jugular vein. After recovery from the surgical procedure, Ceforal 1 gr I.M is given twice a day for seven consecutive days and Dipyrone 1 gr I.M and buprenorphine (0.1 mg/kg) I.M for the initial three days.
- the catheters are used for I.V. medication and blood sampling.
- IVGTT Intravenous Glucose Tolerance Test
- IVGTT is performed. A standard technique is applied: After 12 h fasting, awake animals are infused with 0.5 g/kg of dextrose (10%) I.V via the central venous access. Blood glucose is measured using a glucometer before the injection of dextrose to establish a baseline recording (Time 0) as well as 5, 10, 15, 30, 45, 60, 90, and 120 min after
- pigs Prior to STZ injection, pigs are orally administered 50 g sugar dissolved in 50 ml water via feeding tube (zonda) or PO and with 10% dextrose (0.5gr/Kg BW) via I.V. Blood glucose level is measured using a commercial glucometer. When glucose level drops by a third, approximately 5-vacutainer tubes blood are drawn into serum separator tubes. • Incubate the tubes for 30 minutes at room temperature.
- STZ dissolves immediately prior to the procedure with 100 mmol/L cold sodium citrate buffer solution, pH 4.5 at a final STZ concentration of 80 mg/mL.
- the dissolved STZ is administered I.V. within 5 minutes, the total amount of STZ administered per individual is 150 mg/kg BW.
- the animals are monitored for blood glucose concentrations by means of test strips during wakeup and for 13 hours post STZ injection to avoid hypoglycemia due to insulin release by the destroyed beta cells. Hypoglycemia is promptly treated with an I.V. bolus of glucose at 0.5 g/kg BW.
- Blood glucose level is measured at least twice a day (every day until sacrifice) using a commercial glucometer - at the beginning (fasting) and at the end (after meal) of the day. Clinical examinations performed at least once daily throughout the study. Pigs are observed until stable hyperglycemic (2 weeks). One day before RYGB operation, IVGTT is performed.
- Pigs are operated through an upper midline incision under general anesthesia.
- the gastric pouch ( ⁇ 30 ml) is constructed using linear staplers (GIA80, blue cartridges, Covidien, Mansfield, MA).
- the stomach is divided horizontally, 6 cm from the gastro-esophageal transition (4 cm staple length). With a second stapler, the stomach is vertically completely divided, ending close to the esophagus.
- the small intestine total length: 600 cm) is followed from cecumand proximally to the duodeno-jejunal transition.
- the intestine is divided using a GIA-staple device as above, and a hand-sewn side-to-side anastomosis using continuous 4-0 monofilament absorbable suture is made 150 cm further distally.
- the jejunal end of the Roux limb (alimentary limb) is brought up and anastomosed to the lowest part of the gastric pouch by a linear stapler and completed by continuous monofilament absorbable suture 0-4.
- Blood glucose level is measured at least twice a day (every day until sacrifice) using a commercial glucometer - at the beginning (fasting) and at the end (after meal) of the day. When glucose concentration reaches normal levels, IVGTT is performed (see
- Sacrifice is performed about 14 -21 days post RYGB operation, after blood glucose level have reached normal levels, using the following procedure:
- the serum is subjected to buffer exchange on Sephadex G25 using MES buffer.
- the MES buffered serum is subjected to strong cation exchange fractionation on HiTrap SP HP 5 ml column (GE Healthcare) using the following steps:
- the serum is subjected to size exclusion chromatography on HiLoad Superdex 75 PG (GE Healthcare).
- HiLoad Superdex 75 PG GE Healthcare
- the material eluting 50-55 ml after sample application also contains factor X activity.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 2 diabetes). In another aspect, one or more proteins described herein or compositions containing one or more proteins described herein are provided for. In yet another aspect, compounds, compositions, and methods containing one or more proteins described herein are used for treating a disorder in a patient in need thereof, such as type 2 diabetes.
Description
METHODS AND COMPOUNDS FOR TREATING DIABETES
SEQUENCE LISTING
[00011 The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on September 27, 2018, is named l462-OOl6WOOl_SL.txt and is 2,307,008 bytes in size.
FIELD OF THE DISCLOSURE
[0002] The disclosure provides for compounds, compositions, and methods of use thereof for treating diabetes (e.g., type 2 diabetes) or other disorders. In another aspect, the disclosure provides for one or more proteins described herein or compositions containing the one or more proteins. In yet another aspect, compounds or compositions containing one or more proteins selected from SEQ ID NOs: 1 - 444 described herein are administered to a patient in need thereof to treat diabetes or diabetes related disorders.
BACKGROUND
[0003] Diabetes mellitus (DM), commonly referred to as diabetes, is a major, worldwide medical problem. As of 2015, an estimated 415 million people had diabetes worldwide, with type 2 DM making up about 90% of the cases. This represents 8.3% of the adult population, with equal rates in both women and men. The incidence of DM is increasing in most of the world populations.
[0004] Diabetes is a group of metabolic diseases in which there are high blood sugar levels over a prolonged period. Symptoms of high blood sugar include frequent urination, increased thirst, and increased hunger. If left untreated, diabetes can cause many
complications. Acute complications can include diabetic ketoacidosis, non-ketotic hyperosmolar coma, or death. Serious long-term complications include heart disease, stroke, chronic kidney failure, foot ulcers, and damage to the eyes.
[0005] Diabetes is due to, for example, the pancreas not producing enough insulin or to the cells of the body not responding properly to the insulin produced. There are three main types of diabetes mellitus: (1) Type 1 DM results from the pancreas's failure to produce
enough insulin. This form was previously referred to as“insulin-dependent diabetes mellitus” (IDDM) or“juvenile diabetes”. The cause is unknown. (2) Type 2 DM begins with insulin resistance, a condition in which cells fail to respond to insulin properly. As the disease progresses a lack of insulin may also develop. This form was previously referred to as“non insulin dependent diabetes mellitus” (NIDDM) or“adult-onset diabetes”. The primary cause is excessive body weight and not enough exercise. (3) Gestational diabetes is the third main form and occurs when pregnant women without a previous history of diabetes develop high blood-sugar levels.
[0006] Type 1 DM can be managed with insulin injections. Type 2 DM may be treated with medications with or without insulin. Insulin and some oral medications can cause low blood sugar. Gestational diabetes usually resolves after the birth of the baby.
[0007] A recent study showed that 84 percent of patients who underwent Roux-en-Y gastric bypass (RYGB) experienced complete remission of their type 2 diabetes. Cummings, DE, Endocrine Mechanisms Mediating Remission of Diabetes after Gastric Bypass Surgery, Int J Obes (Lond), 2009 Apr; 33 Suppl 1 :S33-40. The reason for this improvement, however, is not known.
SUMMARY OF THE INVENTION
[0008] In an aspect, the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444; and a pharmaceutically acceptable excipient.
[0009] In an aspect, the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs :439-444; and a pharmaceutically acceptable excipient.
[0010] In an aspect, the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs: 1-444; and a pharmaceutically acceptable excipient.
[0011 ] In an aspect, the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs :439-444; and a pharmaceutically acceptable excipient.
[0012] In an aspect, the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs: 1-444; and a pharmaceutically acceptable excipient.
[0013] In an aspect, the disclosure provides for a pharmaceutical composition comprising one or more proteins selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs :439-444; and a pharmaceutically acceptable excipient.
[0014] In an aspect, the disclosure provides for methods of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1 - 444; and a pharmaceutically acceptable excipient.
[0015] In an aspect, the disclosure provides for methods of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1 - 444, wherein at least one of said one or more proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs:439-444; and a pharmaceutically acceptable excipient.
[0016] In another aspect, the disclosure provides for a method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof. The method comprises administering a pharmaceutical composition including one or more proteins to a patient in need thereof, wherein said one or more proteins are selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444.
[0017] In another aspect, the disclosure provides for a method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof. The method comprises administering a pharmaceutical composition including one or more proteins to a patient in need thereof, wherein said one or more proteins are selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444, and wherein at least one of said one or more proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs:439-444.
[0018] In another aspect, a composition or method described herein comprises only one, only two, only three, only four, or five or more proteins selected from SEQ ID NOs: 1 - 173. In another aspect, a composition or method described herein comprises only one, only two, only three, only four, or five or more proteins selected from SEQ ID NOs: 174 - 444. In another aspect, a composition or method described herein comprises only one, only two, only three, only four, or five or more proteins selected from SEQ ID NOs: 1 - 444.
[0019] In another aspect, an amino acid sequence is at least 98% identical to one of SEQ ID NOs: 1 - 173. In another aspect, an amino acid sequence is at least 98% identical to one of SEQ ID NOs: 174 - 444. In another aspect, an amino acid sequence is at least 98% identical to one of SEQ ID NOs: 1-444.
[0020] In another aspect, an amino acid sequence described herein is at least 99% identical to one of SEQ ID NOs: 1 - 173. In another aspect, an amino acid sequence described herein is at least 99% identical to one of SEQ ID NOs: 174 - 444. In another aspect, an amino acid sequence described herein is at least 99% identical to one of SEQ ID NOs: 1-444.
[0021] In an aspect, a composition or method described herein comprises only one of these proteins. In another aspect, a composition or method described herein comprises only two proteins. In another aspect, a composition or method described herein comprises only three proteins. In another aspect, a composition or method described herein comprises only four proteins. In another aspect, a composition or method described herein comprises five or more proteins.
[0022] In another aspect, a composition described herein is administered to a patient who has not undergone bariatric surgery.
[0023] In another aspect, a composition described herein is administered to a patient who exhibits abnormal insulin resistance, blood glucose level, insulin level, glycosylated hemoglobin level, or a combination thereof.
[0024] In an aspect, the disclosure provides for a pharmaceutical composition
comprising: a protein with an amino acid sequence at least 95% identical to SEQ ID NO 25; and a pharmaceutically acceptable excipient. In another aspect, the protein has an amino acid sequence at least 98% identical to SEQ ID NO 25. In another aspect, the protein has an amino acid sequence at least 99% identical to SEQ ID NO 25.
[0025] In an aspect, the disclosure provides for methods of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including a protein with an amino acid sequence at least 95% identical to SEQ ID NO 25; and a pharmaceutically acceptable excipient.
[0026] In another aspect, the disclosure provides for a method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof, the method comprising administering a pharmaceutical composition comprising a protein to a patient in need thereof, wherein said protein has an amino acid sequence at least 95% identical to SEQ ID NO 25.
[0027] In another aspect, the protein has an amino acid sequence at least 98% identical to SEQ ID NO 25. In another aspect, the protein has an amino acid sequence at least 99% identical to SEQ ID NO 25.
[0028] In another aspect, a composition described herein is administered to a patient who has not undergone bariatric surgery.
[0029] In another aspect, a composition described herein is administered to a patient who exhibits abnormal insulin resistance, blood glucose level, insulin level, glycosylated hemoglobin level, or a combination thereof.
[0030] In another aspect, the disclosure provides for a pharmaceutical composition comprising IGF or a variant thereof, and a pharmaceutically acceptable carrier, wherein the
IGF or variant thereof is present in an effective amount for treating diabetes. Optionally, the composition is suitable for intravenous administration.
[0031 In another aspect, the disclosure provides for a pharmaceutical composition comprising IGF-2 or a variant thereof, and a pharmaceutically acceptable carrier, wherein the IGF-2 or variant thereof is present in an effective amount for treating diabetes. Optionally, the IGF-2 of this aspect is human. Optionally, the human IGF-2 is recombinant. Optionally, the recombinant human IGF-2 variant is at least 85% identical to IGF-2 (SEQ ID NO: 25).
[0032] In another aspect, the disclosure provides for a method of treating diabetes in a subject who has not undergone bariatric surgery comprising administering to a subject in need thereof an effective amount of IGF or a variant thereof. Optionally, the IGF or variant thereof is IGF-2. Optionally, the IGF-2 is administered by intravenous injection. Optionally, the IGF-2 is administered in a single dose.
[0033 ] In another aspect, the disclosure provides for a method of treating diabetes comprising administering to a subject in need thereof an effective amount of human IGF-2 or a variant thereof. Optionally, the human IGF-2 is recombinant.
BRIEF DESCRIPTION OF THE DRAWINGS
[0034] FIG. 1 depicts the blood glucose levels during an experiment in which RYGB was performed on diabetic pigs.
[0035] Figs. 2A and 2B depict the blood glucose levels in an experiment in which the full serum was injected to two diabetic piglets, respectively.
[0036] FIG. 3 depicts the separation of the full serum using cation exchange fractionation into three fractions.
[0037] FIG. 4 depicts how the blood glucose levels changed over time in response to injection of each of the fractions identified in FIG. 3.
[0038] FIG. 5 depicts the separation of the full serum using HiLoad Superdex 75 fractionation into four fractions.
[0039] FIG. 6 depicts how the blood glucose levels changed over time in response to injection of each of the fractions identified in FIG. 5.
[0040] FIG. 7 depicts results from beta cell insulin secretion tests performed using the full serum and two fractions thereof.
[0041] FIG. 8 depicts results from beta cell insulin secretion tests performed using active GLP-land fraction C from the cation exchange process.
[0042] FIGS. 9A and 9B depict the blood glucose levels in an experiment in which rhIGF-2 was injected to two diabetic piglets, respectively.
[0043] FIG. 10 shows that rIGF-2 and AH-2 post-operation serum elevate insulin secretion from beta cells in vitro.
[0044] FIG. 11 depicts additional data showing that post-operation pig serum elevates insulin secretion from beta cells in vitro.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0045] The disclosure provides for biological compounds, such as proteins, as set forth in SEQ ID NOs: 1 - 444. Compositions comprising biological compounds described herein and methods of use thereof are also provided. In an aspect, the disclosure provides for methods of treating a patient in need thereof with a composition comprising, consisting essentially of, or consisting of SEQ ID NOs: 1 - 444. In another aspect, a pharmaceutical composition described herein is administered to a patient who has not undergone bariatric surgery. The disclosure further provides for combinations of SEQ ID NOs: 1 - 444 or combinations of proteins described in Table 1. In an aspect, combinations of SEQ ID NOs: 1 - 444 can be used in a composition to treat a patient in need thereof, wherein the patient has diabetes, type 2 diabetes, cardiac disease, or any disorder related to obesity.
[0046] The term“bariatric surgery” refers, for example, to Roux-en-Y gastric bypass surgery (often called“gastric bypass”), laparoscopic sleeve gastrectomy (often called“the sleeve” or“gastric sleeve”), adjustable gastric band surgery (often called“the band”), and biliopancreatic diversion with duodenal switch gastric bypass (often abbreviated as “BPD/DS”). In an aspect, bariatric surgery is selected from the group consisting of gastric bypass surgery, laparoscopic sleeve gastrectomy, adjustable gastric band surgery, and biliopancreatic diversion with duodenal switch surgery.
[0047] Methods described herein may further comprise reducing at least one of insulin resistance, blood glucose level, obesity, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof in the subject. In an aspect, the disclosure provides for reducing at least one of insulin resistance, blood glucose level, obesity, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof by administering a composition or biological compound described herein, for example, one, two, three, four, five, or more proteins selected from SEQ ID NOs: 1 - 173, SEQ ID NOs: 174 - 444, or SEQ ID NOs: 1 - 444.
TABLE 2
[0048] In an aspect, the disclosure relates to a method of treating diabetes for example, type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising one or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery. In an aspect, the composition further comprises a pharmaceutically acceptable excipient or pharmaceutically acceptable salt.
[0049] In yet another aspect, this disclosure relates to a method of treating diabetes for example, type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and two or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0050] In an aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and three or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0051] In another aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and four or more proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0052] In another aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only one protein selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0053 ] In another aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only two proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0054] In another aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only three proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0055] In another aspect, this disclosure relates to a method of treating type 2 diabetes comprising administering an effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and only four proteins selected from the group consisting of SEQ ID NOs: 1-444 to a patient in need thereof. In an aspect, the patient has not undergone bariatric surgery.
[0056] The active components described for use herein can be included in a
pharmaceutically suitable vehicle, selected to render such compositions amenable to delivery by oral, rectal, parenteral (e.g., intravenous, intramuscular, intraarterial, intraperitoneal, and the like), or inhalation routes, osmotic pump, and the like.
[0057] Pharmaceutical compositions contemplated for use in the practice of the present invention can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting composition contains one or more of the active compounds contemplated for use herein, as active ingredients thereof, in admixture with an organic or inorganic carrier or excipient suitable for nasal, enteral or parenteral applications. The active ingredients may be compounded, for example, with the usual non-toxic, pharmaceutically and physiologically acceptable carriers for tablets, pellets, capsules, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules,
suppositories, solutions, emulsions, suspensions, hard or soft capsules, caplets or syrups or elixirs and any other form suitable for use. The carriers that can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and
other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition, auxiliary, stabilizing, thickening and coloring agents may be used. The active compounds contemplated for use herein are included in the pharmaceutical
composition in an amount sufficient to produce the desired effect upon the target process, condition or disease.
[0058] In addition, such compositions may contain one or more agents selected from flavoring agents (such as peppermint, oil of wintergreen or cherry), coloring agents, preserving agents, and the like, to provide pharmaceutically elegant and palatable
preparations. Tablets containing the active ingredients in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be, for example, (1) inert diluents, such as calcium carbonate, lactose, calcium phosphate, sodium phosphate, and the like; (2) granulating and disintegrating agents, such as corn starch, potato starch, alginic acid, and the like; (3) binding agents, such as gum tragacanth, corn starch, gelatin, acacia, and the like; and (4) lubricating agents, such as magnesium stearate, stearic acid, talc, and the like. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract, thereby providing sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. The tablets may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874, incorporated herein by this reference, to form osmotic therapeutic tablets for controlled release.
[0059] When formulations for oral use are in the form of hard gelatin capsules, the active ingredients may be mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate, kaolin, or the like. They may also be in the form of soft gelatin capsules wherein the active ingredients are mixed with water or an oil medium, for an example, peanut oil, liquid paraffin, olive oil and the like.
[0060] The pharmaceutical compositions may be in the form of a sterile injectable suspension. Such a suspension may be formulated according to known methods using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable excipient, diluent, or solvent, for example, as a solution in l,4-butanediol. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland
fixed oil may be employed including synthetic mono- or diglycerides, fatty acids (including oleic acid), naturally occurring vegetable oils like sesame oil, coconut oil, peanut oil, cottonseed oil, etc., or synthetic fatty vehicles like ethyl oleate or the like. Buffers, preservatives, antioxidants, and the like can be incorporated as required.
[0061 ] In addition, sustained release systems, including semi-permeable polymer matrices in the form of shaped articles (e.g., films or microcapsules) can also be used for the administration of the active compound employed herein.
[0062] In accordance with another aspect of the present invention, there are provided methods for the treatment of a subject having diabetes mellitus, said method comprising administering to said subject an effective amount of a composition comprising metformin and one or more of a bioavailable source of chromium, vanadium, or magnesium, or a
pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier. All combinations, sources and amounts of the active ingredients discussed herein in conjunction with the compositions of the present invention are contemplated as being administered in accordance with the methods disclosed herein.
[0063] As will be appreciated by those of skill in the art, diabetes presents a complicated array of conditions and symptoms including abnormal glucose metabolism, insulin resistance, hyperinsulinemia, hyperglycemia, hypertriglyceridemia, elevated LDL, lowered HDL and elevated blood pressure. Because of the interrelatedness of these conditions and symptoms, invention compositions are useful in treating many of them.
Isolated Nucleic Acid Molecules, and Variants and Fragments Thereof
[0064] In an aspect, the disclosure provides for isolated or recombinant nucleic acid molecules comprising nucleotide sequences encoding proteins described herein, for example, SEQ ID NOs: 1 - 444. In another aspect, the disclosure provides for isolated or recombinant nucleic acid molecules comprising nucleotide sequences encoding proteins described herein, for example, SEQ ID NOs: 1 - 173 or SEQ ID NOs: 174 - 444.
[0065] In an aspect, proteins of the present invention are encoded by a nucleotide sequence. In an aspect, the disclosure provides for a nucleotide sequence encoding an amino acid sequence that has at least about 60% about 65%, about 70% about 75%, about 80% about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about
96%, about 97%, about 98%, about 99% or greater sequence identity to SEQ ID NOs: 1 - 444. In another aspect, proteins of the present invention are encoded by a nucleotide sequence. In an aspect, the disclosure provides for a nucleotide sequence encoding an amino acid sequence that has at least about 60% about 65%, about 70% about 75%, about 80% about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or greater sequence identity to SEQ ID NOs: 1 - 173 or SEQ ID NOs: 174 - 444.
[0066] The skilled artisan will further appreciate that changes can be introduced by mutation of the nucleotide sequences of the invention thereby leading to changes in the amino acid sequence of the encoded proteins, without altering the biological activity of the proteins. Thus, variant isolated nucleic acid molecules can be created by introducing one or more nucleotide substitutions, additions, or deletions into the corresponding nucleotide sequence disclosed herein, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein. Mutations can be introduced by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Such variant nucleotide sequences are also encompassed by the present invention.
[0067] For example, conservative amino acid substitutions may be made at one or more, predicted, nonessential amino acid residues. A“nonessential” amino acid residue is a residue that can be altered from the wild-type sequence of a protein described herein without altering the biological activity, whereas an“essential” amino acid residue is required for biological activity. A“conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine ), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains ( e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).
[0068] Amino acid substitutions may be made in nonconserved regions that retain function. In general, such substitutions would not be made for conserved amino acid residues, or for amino acid residues residing within a conserved motif, where such residues are
essential for protein activity. Examples of residues that are conserved and that may be essential for protein activity include, for example, residues that are identical between all proteins contained in an alignment of similar or related toxins to the sequences of the invention (e.g., residues that are identical in an alignment of homologous proteins). Examples of residues that are conserved but that may allow conservative amino acid substitutions and still retain activity include, for example, residues that have only conservative substitutions between all proteins contained in an alignment of similar or related toxins to the sequences of the invention (e.g., residues that have only conservative substitutions between all proteins contained in the alignment homologous proteins). However, one of skill in the art would understand that functional variants may have minor conserved or nonconserved alterations in the conserved residues.
Isolated Proteins and Variants and Fragments Thereof
[0069] “Fragments” or“biologically active portions” include protein fragments comprising amino acid sequences sufficiently identical to the amino acid sequence set forth in SEQ ID NOs: 1-444, and that exhibit, for example, anti-diabetic activity.
[0070] By“variants” is intended proteins having an amino acid sequence that is at least about 60%, 65%, about 70%, 75%, about 80%, 85%, about 90%, 91 %, 92%, 93%, 94%,
95%, 96%, 97%, 98% or 99% identical to the amino acid sequence of any of SEQ ID NOs: 1 - 173, SEQ ID NOs: 174 - 444; or SEQ ID NOs: 1-444. Variants include proteins that differ in amino acid sequence due to mutagenesis. Variant proteins encompassed by the present invention are biologically active, that is they continue to possess the desired biological activity of the native protein, that is, retaining anti diabetic activity. In some embodiments, the variants have improved activity relative to the native protein.
[0071] In various embodiments of the present invention, anti-diabetic proteins include amino acid sequences that are shorter than the full-length sequences due to the use of an alternate downstream start site.
[0072] Antibodies to the proteins of the present invention, or to variants or fragments thereof, are also encompassed. Methods for producing antibodies are well known in the art (see, for example, Harlow and Lane (1988 ) Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY; Ei.S. Patent No. 4,196,265).
[0073 ] Thus, one aspect of the invention concerns antibodies, single-chain antigen binding molecules, or other proteins that specifically bind to one or more of the protein or protein molecules of the invention and their homologs, fusions or fragments. In a particularly preferred embodiment, the antibody specifically binds to a protein having the amino acid sequence set forth in SEQ ID NOs: 1-444 or a fragment thereof. In another embodiment, the antibody specifically binds to a fusion protein comprising an amino acid sequence selected from the amino acid sequence set forth in SEQ ID NOs: 1-444 or a fragment thereof.
[0074] Antibodies of the invention may be used to quantitatively or qualitatively detect the protein or protein molecules of the invention, or to detect post translational modifications of the proteins. As used herein, an antibody or protein is said to“specifically bind” to a protein or protein molecule of the invention if such binding is not competitively inhibited by the presence of non-related molecules.
[0075] The antibodies of the invention may be contained within a kit useful for detection of the protein or protein molecules of the invention. The invention further comprises a method of detecting the protein or protein molecule of the invention (particularly a protein encoded by the amino acid sequence set forth in SEQ ID NOs: 1-444, including variants or fragments thereof that are capable of specifically binding to the antibody of the invention) comprising contacting a sample with the antibody of the invention and determining whether the sample contains the protein or protein molecule of the invention. Methods for utilizing antibodies for the detection of a protein or protein of interest are known in the art.
Altered or Improved Variants
[0076] It is recognized that DNA sequences of a protein may be altered by various methods, and that these alterations may result in DNA sequences encoding proteins with amino acid sequences different than that encoded by a protein of the present invention. This protein may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions of one or more amino acids of SEQ ID NOs: 1-444, including up to about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, about 50, about 55, about 60, about 65, about 70, about 75, about 80, about 85, about 90, about 100, about 105, about 110, about 115, about 120, about 125, about 130, about 135, about 140, about 145, about 150, about 155, or more amino acid substitutions, deletions or insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of a
protein can be prepared by mutations in the DNA. This may also be accomplished by one of several forms of mutagenesis and/or in directed evolution. In some aspects, the changes encoded in the amino acid sequence will not substantially affect the function of the protein. Such variants will possess the desired anti-diabetic activity.
[0077] Alternatively, alterations may be made to the protein sequence of many proteins at the amino or carboxy terminus without substantially affecting activity. This can include insertions, deletions, or alterations introduced by modem molecular methods, such as PCR, including PCR amplifications that alter or extend the protein coding sequence by inclusion of amino acid encoding sequences in the oligonucleotides utilized in the PCR amplification. Alternatively, the protein sequences added can include entire protein-coding sequences, such as those used commonly in the art to generate protein fusions. Such fusion proteins are often used to (1) increase expression of a protein of interest (2) introduce a binding domain, enzymatic activity, or epitope to facilitate either protein purification, protein detection, or other experimental uses known in the art (3) target secretion or translation of a protein to a subcellular organelle, such as the periplasmic space of Gram-negative bacteria, or the endoplasmic reticulum of eukaryotic cells, the latter of which often results in glycosylation of the protein.
Theory of Operation
[0078] In healthy subjects, insulin is the substance that regulates glucose uptake. But in diabetic subjects, insulin no longer performs that role effectively (due to either inadequate levels of insulin or insulin resistance). It has been determined that a substance referred to herein as“factor X” can be used to resolve type II diabetes.
[0079] While not wishing to be bound by theory, the following is one possible
explanation of the mechanism of action of the disclosed invention. The inventor theorizes that certain cells in the body, referred to herein as“BLC” (which stands for beta-like cells) can be induced to secrete either insulin or an insulin-like material (“ILM”) in response to high levels of glucose. Note that while the location of the BLC within the body has not yet been identified, knowledge of their location is not necessary to obtain the results described herein.
[0080] More specifically, before the BLC are exposed to factor X, the BLC are dormant or inactivated, in which case they do not secrete insulin or ILM or secrete an insufficient amount of insulin or ILM. But after exposure to factor X, the BLC become activated, and will
begin to secrete insulin or ILM in response to high levels of glucose. One possible mechanism of action is that exposure to factor X causes the BLC to secrete insulin and/or ILM in response to high levels of glucose. Another possible mechanism of action is that the BLC are naturally programmed to secrete insulin and/or ILM in response to high levels of glucose, but an unknown substance that deactivates the BLC is ordinarily present. Under this scenario, factor X neutralizes (e.g., switches off) this normally prevailing deactivation substance.
[0081] In either scenario, once the BLC have been activated, the BLC will sense the level of glucose in the blood, and will initiate the production of insulin or ILM at levels that correspond to the level of glucose in the blood (so that higher levels of glucose will result in the production of more insulin or ILM). This production of insulin or ILM may occur either directly in the BLC themselves or indirectly (e.g. through the action of other cells). The insulin or ILM circulates in the blood.
[0082] Another possible explanation of the mechanism of action of the disclosed invention is that exposure to factor X improves conventional beta cells’ ability to regulate the glucose levels in a subject’s body, or downregulates / turns off another mechanism that prevents the conventional beta cells from properly regulating glucose levels.
[0083] Under either explanation, factor X is ordinarily either not present (at least in sufficient quantities) or switched off in diabetic animals that have not undergone RYGB. But bariatric surgery (e.g., RYGB) results in the appearance or upregulation of factor X in the blood of those animals, which ultimately resolves those animals’ diabetes. And most notably, when factor X is obtained from the blood of the post-RYGB animals (whose diabetes has been resolved) and subsequently injected into other diabetic animals (that have not undergone RYGB), the diabetes of the latter animals was also resolved. This indicates that factor X can be used as a non-surgical treatment for diabetes.
[0084] The first step in testing this theory was inducing diabetes mellitus in adult pigs using STZ to destroy the beta cells of the pancreas, and subsequently performing RYGB on those pigs. FIG. 1 depicts the blood glucose levels during this experiment for a set of pigs. Even though their pancreas beta cells were destroyed, the glucose level in these post-RYGB pigs dropped significantly within days following RYGB operation and remained low for the duration of the experiment. Numerically, the blood glucose level dropped from 448 mg/dl
pre-operation to 200 mg/dl post-operation, with a P-value of < 0.01 (n=7). In addition, the C- peptide concentration increased from 0 pM pre-operation to 39 pM post-operation, with a P- value of < 0.01 (n=7). These values indicate behavior that is more like that of normal pigs as opposed to diabetic pigs, indicating that the pigs’ diabetes was resolved. -
[0085] The inventor refers to the substance responsible for the normalization of the glucose levels in these post-RYGB pigs as“factor X” herein. Blood samples were extracted from these post-RYGB pigs for further testing as described below and to isolate factor X, after which the pigs were sacrificed.
[0086] The animal procedures that were followed to harvest blood samples that contained factor X are reproduced below in Appendix A. To summarize those procedures, adult pigs were treated with streptozotocin (STZ) to destroy their pancreas, and fasting blood glucose level was monitored until steady diabetes was present. Then, RYGB was performed on the adult pigs, and their blood glucose was monitored daily up to 7 days until normal glucose levels were restored. Most of the pig’s Blood was then withdrawn from the post-RYGB adult pigs into serum separator tubes and the pigs were then sacrificed.
[0087] Tests on the blood samples that were extracted from the pigs showed either no insulin or only small quantities of insulin in the plasma. This indicates either that ILM circulating in the pig’s blood (and not insulin) that was influencing/regulating glucose levels (and/or glucose/carbohydrate metabolism) or that factor X enhanced the efficacy of insulin, or both.
[0088] The blood samples were processed into a serum (referred to herein as“full serum”) as described below in Appendix B. And after inducing diabetes into a set of piglets using STZ, additional experiments were performed on the diabetic piglets.
[0089] Figs. 2A and 2B depict the results of one experiment in which the full serum was injected to diabetic piglets. For both the FIG. 2 A piglet and the FIG. 2B piglet, the blood glucose level dropped significantly a few days after injection of the full serum, and remained low for the duration of the experiment. This data indicates that factor X was present in the full serum, and that factor X can be used as an injectable treatment for diabetes.
[0090] Additional experiments were also performed by separating the full serum into fractions using two alternative fractionation procedures (cation exchange chromatography
and size exclusion chromatography) described below in Appendix B, and the efficacy of the various fractions obtained were tested.
[0091] FIG. 3 depicts the separation of the full serum using cation exchange fractionation on HiTrap SP HP 5 ml column (GE Healthcare) into three fractions labeled A, B, and C. Each of those three fractions was then tested by injecting the respective fraction into diabetic piglets who had not undergone RYGB. FIG. 4 depicts how the blood glucose levels changed over time in response to injection of each of these three fractions. A review of this data reveals that fraction C was the most effective in reducing the blood glucose level to the point that the diabetes appears to be resolved, and that the reduction persisted through 17 days after injection. This data indicates that factor X (plus additional proteins) was present in fraction C from the cation exchange process fractionation.
[0092] FIG. 5 depicts the separation of the full serum using a HiLoad Superdex 75 PG (GE Healthcare) gel filtration process into four fractions labeled A, B, C, and D. Each of those four fractions was then tested by injecting the respective fraction into diabetic piglets who had not undergone RYGB. FIG. 6 depicts how the blood glucose levels changed over time in response to injection of each of these four fractions. A review of this data reveals that fraction B was the most effective in reducing the blood glucose level to the point that the diabetes appears to be resolved and that the reduction persisted through 17 days after injection. This data indicates that factor X (plus additional proteins) was present in fraction B from the Superdex-75 gel filtration process fractionation.
[0093] Fraction C from the cation exchange process and fraction B from the Superdex-75 gel filtration process are referred to herein as eluate I and eluate II, respectively. Collectively, this data indicates that a single injection of a serum or eluate that includes factor X provides significant resolution of diabetes, with a very long-lasting duration (at least on the order of two weeks).
[0094] To confirm these results, beta cell insulin secretion tests were performed using the full serum diluted 1 :4, 1 :10, and 1 :20; and using fractions B and C from the cation exchange process, each diluted 1 :4, 1 : 10, and 1 :20. FIG. 7 depicts these results, which confirm that fraction C from the cation exchange process was the most effective. Beta cell insulin secretion tests were also performed using a control, active GLP-l (a compound known to boost insulin secretion), and fraction C from the cation exchange process. FIG. 8 depicts
these results, which show that fraction C from the cation exchange process was the most effective.
[0095] A first set of relevant porcine proteins was identified using mass spectrometry from the two active fractions (i.e., fraction C of the cation exchange process and fraction B of the Superdex-75 gel filtration process). And a second set of relevant proteins was identified by finding the human counterparts of the first set of porcine proteins.
[0096] Without being bound by theory, from this work it was concluded that (a) factor X is not ordinarily present (at least in sufficient quantities) to control diabetes in diabetic subjects that have not undergone RYGB or other types of bariatric surgery; and (b) introducing factor X into diabetic subjects is an effective way of obtaining long-lasting control of diabetes in those subjects.
[0097] Additional tests were then performed and are still ongoing to narrow down which protein was responsible for the resolution of the piglets’ diabetes. In one such test, recombinant human IGF-2 (“rhIGF-2”) was injected intravenously into two diabetic pigs, and the effect on glucose levels was monitored. More specifically, a single intravenous injection (500ug) of rhIGF-2 was injected into a 16 kg Delta-4 pig and a 9 kg AH-l pig. The difference in weight of those two pigs corresponded to two different dosages (30 pg/kg and 55 pg/kg) FIGS. 9A and 9B depict the resulting change in those pigs’ glucose levels over time, and the data in those figures show that hIGF-2 administered to pigs result in glucose levels returning to normal levels (relative to pre-treatment levels). It is important to note that while FIGS. 9A and 9B depict dramatic improvements in the blood glucose levels of two particular pigs, when similar tests were performed on other pigs, the other pigs’ diabetes was not resolved. Further investigation into why the treatment was effective for some of the pigs and not others will be required.
[0098] Further study of the anti-diabetic activity of IGF-2 revealed inhibition of insulin/IGF receptor family using Tocris GSK1838705 inhibitor (#5111) in vitro. More specifically, testing revealed that adding an IGF receptor inhibitor reduced glucose uptake relative to insulin alone from 7500 to 1300 Em. (540nm) and relative to a post-RYGB serum alone from 15500 to 4500 Em. (540nm), which provides additional evidence that IGF-2 can be responsible for the reduction in glucose in certain circumstances. Similarly, adding an IGF-2 blocking antibody also reduced glucose uptake relative to post-RYGB serum alone
from 13500 to 3000 Em. (540nm), which confirms the same point. Finally, rhIGF-2 was compared to insulin in a glucose uptake assay at concentrations of 10, 100, and 1000 nM. The data for the insulin at those three concentrations was 7000, 8000, and 8500 Em. (540nm), respectively; and the data for the rhIGF-2 at those three concentrations was 2000, 4000, and 7600 Em. (540nm), respectively, indicating that high concentrations of rhIGF-2 increases glucose uptake to a similar extent as insulin.
[0099] Mass spec analysis and Western blot analysis confirmed that IGF-2 was present in both of the active fractions and in the full serum, and that the level of IGF-2 complex in pigs increased after the RYGB operation.
[00100] In additional testing, IGF-2 was found to stimulate insulin release from MIN6 beta cell line. Transgenic C57BL/6 mouse insulinoma cell line (MIN6) cells originate from a transgenic C57BL/6 mouse insulinoma expressing an insulin-prom oter/T-antigen construct. MIN-6 cells express GLUT -2 and glucokinase and respond to glucose within the
physiological range in the presence of nicotinamide (Miyazaki et ah, 1990).
[0010 !] To measure insulin secretion in response to factor-X, MIN6 cells were plated in 24-well culture plates at 3 c 105 cells/well. After 48 hr, cells were washed twice and preincubated in serum free medium (DMEM 25 mM glucose, 2 mM l-glutamine, and 1 mM sodium pyruvate) for 1 hr. Following pre-incubation step, factor-X induction performed by culturing cells for 3 hr with 500 pl of serum free medium supplemented with 5% post RYGB serum/fractions. Finally, induction medium was replaced with new 500 mΐ of serum free medium for 3 hr and collected (stored at -20 °C until assayed) for insulin ELISA analysis (Mercodia Mouse Insulin ELISA #10-1247-01).
[00102] FIG. 10 shows that rIGF-2 and AH-2 post-operation serum elevate insulin secretion from beta cells in vitro. In FIG. 10 the bars in the second grouping represent beta cells induction with recombinant human IGF-2, and the bars on the right side of the final four groupings represent 3 days post operation serum. FIG. 11 contains additional data (from experiment“Delta-6”) showing that delta-6 post-operation pig serum elevates insulin secretion from beta cells in vitro. Here again, the bars on the right side of each grouping represent three days post operation serum. In both FIGS. 10 and 11, 5% of the pre-operation serum or post-operation serum was diluted in a serum free medium with 3 hr of incubation.
Collection of cultured medium for analysis was done using 3 hr incubation with new 0.5 mL serum free medium.
[00103] 444 individual aspects of the invention correspond, respectively, to each of the
444 SEQ ID NOs that appear on tables 1 and 2. For each of those SEQ ID NOs, the respective aspect of the invention provides for a pharmaceutical composition including a protein with an amino acid sequence at least 95% identical to the respective SEQ ID NO and a pharmaceutically acceptable excipient. In any of these 444 aspects, the amino acid sequence of the protein may optionally be at least 98% identical or at least 99% identical to the respective SEQ ID NO.
[00104] Another 444 individual aspects of the invention correspond, respectively, to each of the 444 SEQ ID NOs that appear on tables 1 and 2. For each of those SEQ ID NOs, the respective aspect of the invention provides for a method of treating diabetes in a patient in need thereof comprising administering an effective amount of a pharmaceutical composition including a protein with an amino acid sequence at least 95% identical to the respective SEQ ID NO and a pharmaceutically acceptable excipient. In any of these 444 aspects, the amino acid sequence of the protein may optionally be at least 98% identical or at least 99% identical to the respective SEQ ID NO.
[00105] Another aspect of the invention provides a pharmaceutical composition according any of the aspects described above for use in the treatment of diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
[00106] Another aspect of the invention provides a pharmaceutical composition according to any of the aspects described above for use as a medicament.
[00107] Another aspect of the invention provides one or more proteins selected from the group consisting of an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to one of SEQ ID NOs: 1-444 for use as a medicament.
[00108 ] Another aspect of the invention provides one or more proteins selected from the group consisting of an amino acid sequence at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to one of SEQ ID NOs: 1-444 for use in the treatment of
diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
[00109] Another aspect of the invention provides a pharmaceutical composition comprising IGF-2 or a variant thereof for use as a medicament.
[001 10] Another aspect of the invention provides a pharmaceutical composition comprising IGF-2 or a variant thereof for use in the treatment of diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
[0011 1 ] References cited in this disclosure are incorporated herewith in their entirety.
[0 112] While the present invention has been disclosed with reference to certain embodiments, numerous modifications, alterations, and changes to the described embodiments are possible without departing from the sphere and scope of the present invention, as defined in the appended claims. Accordingly, it is intended that the present invention not be limited to the described embodiments, but that it has the full scope defined by the language of the following claims, and equivalents thereof.
APPENDIX A: Animal Procedures
[00113] The following procedure was used to harvest blood samples containing factor X. Acclimation of Pigs:
[00114] The pigs are housed individually under standardized conditions (l9-23°C; 40-70% relative humidity; 12: 12 hour day/night cycle).
Cannulation:
[00115] After acclimation, the pigs undergo surgery, which consists of an indwelling silicon catheter into the jugular vein under aseptic conditions. In brief, after an overnight fast, preoperative intramuscular (I.M) ketamine (20 mg/kg) + xylazine (2 mg/kg) is injected, and then insertion of catheter (Venflon) into the ear vein and injection of midazolam
intravenously (I.V). Before the procedure, the pigs are injected with Ceforal 1 gr I.M and Dipyrone 1 gr I.M.
[00116] The pigs are intubated and general anesthesia maintained with isoflurane vaporized in oxygen. The concentration of isoflurane (1 - 2.5%) continuously adjusted to achieve an adequate depth of anesthesia. The silicon catheter is inserted into the jugular vein. After recovery from the surgical procedure, Ceforal 1 gr I.M is given twice a day for seven consecutive days and Dipyrone 1 gr I.M and buprenorphine (0.1 mg/kg) I.M for the initial three days. The catheters are used for I.V. medication and blood sampling.
Intravenous Glucose Tolerance Test (IVGTT):
[001 17] IVGTT is performed. A standard technique is applied: After 12 h fasting, awake animals are infused with 0.5 g/kg of dextrose (10%) I.V via the central venous access. Blood glucose is measured using a glucometer before the injection of dextrose to establish a baseline recording (Time 0) as well as 5, 10, 15, 30, 45, 60, 90, and 120 min after
administration of dextrose.
Induction of Diabetes Mellitus by STZ:
[0011.8] Prior to STZ injection, pigs are orally administered 50 g sugar dissolved in 50 ml water via feeding tube (zonda) or PO and with 10% dextrose (0.5gr/Kg BW) via I.V. Blood glucose level is measured using a commercial glucometer. When glucose level drops by a third, approximately 5-vacutainer tubes blood are drawn into serum separator tubes.
• Incubate the tubes for 30 minutes at room temperature.
• Centrifuge at 1250 g for 10 minutes at RT (room temperature).
• Collect the supernatant and pipette 5 x 1 ml aliquots in 1.5 ml tubes, and 6 x 5 ml aliquots in 15 ml tubes.
• Freeze at -80°C.
[00319] Due to the short half-life of STZ, STZ dissolves immediately prior to the procedure with 100 mmol/L cold sodium citrate buffer solution, pH 4.5 at a final STZ concentration of 80 mg/mL.
• Dissolve STZ in the Na-Citrate buffer
• Vortex until STZ is completely in solution.
• Filter-sterilize (0.45 pm)
[00120] The dissolved STZ is administered I.V. within 5 minutes, the total amount of STZ administered per individual is 150 mg/kg BW. At the end of the procedure, the animals are monitored for blood glucose concentrations by means of test strips during wakeup and for 13 hours post STZ injection to avoid hypoglycemia due to insulin release by the destroyed beta cells. Hypoglycemia is promptly treated with an I.V. bolus of glucose at 0.5 g/kg BW.
[00121] Blood glucose level is measured at least twice a day (every day until sacrifice) using a commercial glucometer - at the beginning (fasting) and at the end (after meal) of the day. Clinical examinations performed at least once daily throughout the study. Pigs are observed until stable hyperglycemic (2 weeks). One day before RYGB operation, IVGTT is performed.
Roux-en-Y Gastric Bypass Operation (RYGB):
[00122] Pigs are operated through an upper midline incision under general anesthesia. The gastric pouch (~30 ml) is constructed using linear staplers (GIA80, blue cartridges, Covidien, Mansfield, MA). The stomach is divided horizontally, 6 cm from the gastro-esophageal transition (4 cm staple length). With a second stapler, the stomach is vertically completely divided, ending close to the esophagus. The small intestine (total length: 600 cm) is followed from cecumand proximally to the duodeno-jejunal transition. Seventy centimeters from the duodeno-jejunal junction, the intestine is divided using a GIA-staple device as above, and a hand-sewn side-to-side anastomosis using continuous 4-0 monofilament absorbable suture is
made 150 cm further distally. The jejunal end of the Roux limb (alimentary limb) is brought up and anastomosed to the lowest part of the gastric pouch by a linear stapler and completed by continuous monofilament absorbable suture 0-4.
Follow-Up After Surgery:
[00123 ] Blood glucose level is measured at least twice a day (every day until sacrifice) using a commercial glucometer - at the beginning (fasting) and at the end (after meal) of the day. When glucose concentration reaches normal levels, IVGTT is performed (see
Intravenous Glucose Tolerance Test above)
Blood Extraction and Sacrifice:
[00124] Sacrifice is performed about 14 -21 days post RYGB operation, after blood glucose level have reached normal levels, using the following procedure:
• Pigs are kept fasting overnight.
• The animals are anaesthetized.
• 50 g sugar dissolved in 50 ml water is orally infused via feeding tube (zonda).
• 10% Dextrose (0.5 gr/kg BW) is administrated I.V. to stimulate the secretion of anti-diabetic factors.
• Blood glucose level is measured using a commercial glucometer.
• When glucose level drops to 2/3 of the peak-or after 30 min, maximum
volume of blood samples is withdrawn into serum separator tubes.
• The animal is then sacrificed.
APPENDIX B: Purification Procedures:
[00125] The blood samples that were extracted from the pigs were prepared using the following procedure:
• Blood is incubated for 30 minutes at room temperature.
• Blood is centrifuged at 1250 g for 10 minutes at room temperature.
• The supernatant (serum) is collected, aliquoted and frozen at -80°C.
[00126] The resulting serum was then purified and separated into different fractions using the fractionation approaches described below.
Fractionation by Cation Exchange Chromatography:
[00127] The serum is subjected to buffer exchange on Sephadex G25 using MES buffer. The MES buffered serum is subjected to strong cation exchange fractionation on HiTrap SP HP 5 ml column (GE Healthcare) using the following steps:
• Sample application;
• Wash in MES buffer with 168 mM KC1
• Elution in MES buffer with 445 mM KC1.
[00128] The resulting elution fraction contains factor X activity.
Fractionation by Size Exclusion Chromatography:
[00129] The serum is subjected to size exclusion chromatography on HiLoad Superdex 75 PG (GE Healthcare). The material eluting 50-55 ml after sample application also contains factor X activity.
Buffer Compositions:
[00130] PBS, pH 7.4 (Biological Industries #02-023-5A)
Claims
1. A pharmaceutical composition comprising:
one or more proteins selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs :439-444; and
a pharmaceutically acceptable excipient.
2. A pharmaceutical composition comprising:
one or more proteins selected from the group consisting of an amino acid sequence at least 98% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 9598 identical to one of SEQ ID NOs:439-444; and
a pharmaceutically acceptable excipient.
3. A pharmaceutical composition comprising:
one or more proteins selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs: 1-444, wherein at least one of said proteins is selected from the group consisting of an amino acid sequence at least 99% identical to one of SEQ ID NOs :439-444; and
a pharmaceutically acceptable excipient.
4. The pharmaceutical composition according to any of claims 1-3 wherein said
composition comprises only one of said proteins.
5. The pharmaceutical composition according to any of claims 1-3, wherein said
composition comprises only two of said proteins.
6. The pharmaceutical composition according to any of claims 1-3, wherein said
composition comprises only three of said proteins.
7. The pharmaceutical composition according to any of claims 1-3, wherein said composition comprises only four of said proteins.
8. The pharmaceutical composition according to any of claims 1-3, wherein said
composition comprises five or more of said proteins.
9. The pharmaceutical composition according to any of claims 1-8, wherein said one or more proteins are selected from the group consisting of SEQ ID NOs: 1 - 173.
10. The pharmaceutical composition according to any of claims 1-8, wherein said one or more proteins are selected from the group consisting of SEQ ID NOs: 174 - 444.
11. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 1 to a patient in need thereof.
12. The method of claim 11, wherein said patient has not undergone bariatric surgery.
13. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 2 to a patient in need thereof.
14. The method of claim 13, wherein said patient has not undergone bariatric surgery.
15. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 3 to a patient in need thereof.
16. The method of claim 15, wherein said patient has not undergone bariatric surgery.
17. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 4 to a patient in need thereof.
18. The method of claim 17, wherein said patient has not undergone bariatric surgery.
19. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 5 to a patient in need thereof.
20. The method of claim 19, wherein said patient has not undergone bariatric surgery.
21. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 6 to a patient in need thereof.
22. The method of claim 21, wherein said patient has not undergone bariatric surgery.
23. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 7 to a patient in need thereof.
24. The method of claim 23, wherein said patient has not undergone bariatric surgery.
25. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 8 to a patient in need thereof.
26. The method of claim 25, wherein said patient has not undergone bariatric surgery.
27. A method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof, the method comprising:
administering a pharmaceutical composition comprising one or more proteins to a patient in need thereof, wherein said one or more proteins are selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs: 1- 444, and wherein at least one of said one or more proteins is selected from the group consisting of an amino acid sequence at least 95% identical to one of SEQ ID NOs:439-444.
28. The method of claim 27, wherein said composition comprises only one of said
proteins.
29. The method of claim 27, wherein said composition comprises only two of said
proteins.
30. The method of claim 27, wherein said composition comprises three or more of said proteins.
31. The method according to any of claims 27-30, wherein said patient has not undergone bariatric surgery.
32. The method according to any of claims 27-31, wherein said one or more proteins are selected from the group consisting of SEQ ID NOs: 1 - 173.
33. The method according to any of claims 27-31, wherein said one or more proteins are selected from the group consisting of SEQ ID NOs: 174 - 444.
34. A pharmaceutical composition comprising:
a protein with an amino acid sequence at least 95% identical to SEQ ID NO 25; and a pharmaceutically acceptable excipient.
35. The pharmaceutical composition of claim 34, wherein the protein has an amino acid sequence at least 98% identical to SEQ ID NO 25.
36. The pharmaceutical composition of claim 34, wherein the protein has an amino acid sequence at least 99% identical to SEQ ID NO 25.
37. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 34 to a patient in need thereof.
38. The method of claim 37, wherein said patient has not undergone bariatric surgery.
39. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 35 to a patient in need thereof.
40. The method of claim 39, wherein said patient has not undergone bariatric surgery.
41. A method of treating diabetes comprising administering an effective amount of a pharmaceutical composition according to claim 36 to a patient in need thereof.
42. The method of claim 41, wherein said patient has not undergone bariatric surgery.
43. A method of treating diabetes, abnormal insulin resistance, abnormal blood glucose level, abnormal insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof, the method comprising:
administering a pharmaceutical composition comprising a protein to a patient in need thereof, wherein said protein has an amino acid sequence at least 95% identical to SEQ ID NO 25.
44. The method of claim 43, wherein said patient has not undergone bariatric surgery.
45. A pharmaceutical composition, comprising IGF or a variant thereof, and a
pharmaceutically acceptable carrier, wherein the IGF or variant thereof is present in an effective amount for treating diabetes.
46. The pharmaceutical composition according to claim 45, wherein the IGF or variant thereof is IGF -2.
47. The pharmaceutical composition according to claim 46, wherein the IGF-2 is human.
48. The pharmaceutical composition according to claim 47, wherein the human IGF-2 is recombinant.
49. The pharmaceutical composition according to claim 48, wherein the variant is at least 85% identical to IGF-2 (SEQ ID NO: 25).
50. The pharmaceutical composition according to claim 45, wherein the composition is suitable for intravenous administration.
51. The pharmaceutical composition according to claim 45, wherein the diabetes is type 1 diabetes.
52. The pharmaceutical composition according to claim 45, wherein the diabetes is type 2 diabetes.
53. The pharmaceutical composition according to claim 45, wherein the composition does not comprise stem cells, progenitor cells, other growth factors, or a caspase inhibitor.
54. A method of treating diabetes, comprising administering to a subject in need thereof an effective amount of IGF or a variant thereof.
55. The method according to claim 54, wherein the IGF or variant thereof is IGF-2.
56. The method according to claim 55, wherein the IGF-2 is administered by intravenous injection.
57. The method according to claim 55, wherein the IGF-2 is administered in a single dose.
58. The method according to claim 55, wherein the IGF-2 is human.
59. The method according to claim 55, wherein the IGF-2 is recombinant.
60. The method according to claim 54, wherein the subject presents type 1 diabetes.
61. The method according to claim 54, wherein the subject presents type 2 diabetes.
62. The method according to claim 54, wherein the subject has not undergone bariatric surgery.
63. The method according to claim 54, wherein the subject exhibits abnormal insulin resistance, blood glucose level, insulin level, hyperinsulinemia, glycosylated hemoglobin level, or a combination thereof.
64. The method according to claim 55, wherein the IGF-2 is administered as a
composition not comprising stem cells, progenitor cells, other growth factors, or a caspase inhibitor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/057643 WO2020070540A1 (en) | 2018-10-02 | 2018-10-02 | Methods and compounds for treating diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2018/057643 WO2020070540A1 (en) | 2018-10-02 | 2018-10-02 | Methods and compounds for treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020070540A1 true WO2020070540A1 (en) | 2020-04-09 |
Family
ID=70054461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2018/057643 WO2020070540A1 (en) | 2018-10-02 | 2018-10-02 | Methods and compounds for treating diabetes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2020070540A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011159882A2 (en) * | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Novel stabilized insulin agonists |
US20170210781A1 (en) * | 2014-06-05 | 2017-07-27 | Oxford University Innovation Limited | Polypeptides and uses thereof |
-
2018
- 2018-10-02 WO PCT/IB2018/057643 patent/WO2020070540A1/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011159882A2 (en) * | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Novel stabilized insulin agonists |
US20170210781A1 (en) * | 2014-06-05 | 2017-07-27 | Oxford University Innovation Limited | Polypeptides and uses thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3609522A2 (en) | Methods and compounds for treating diabetes | |
JP5695097B2 (en) | GLP-1, EXENDIN-4, peptide analogue thereof and use thereof | |
JP2021185178A (en) | Methods for treatment of bile acid-related disorders | |
EA013821B1 (en) | Human proislet peptide, derivatives and analogs thereof, and methods of using same | |
CN113265007B (en) | Fusion protein for treating metabolic diseases and preparation method and application thereof | |
JP2021508037A (en) | Products and methods for assessing and improving Klotho protein levels | |
US20120082642A1 (en) | Reversal of Adult Onset Disorders with Granulocyte-Colony Stimulating Factors | |
JP4772884B2 (en) | Pharmaceutical composition for suppressing an increase in blood glucose level and use of a polypeptide for producing a drug for suppressing an increase in blood glucose level | |
WO2020070540A1 (en) | Methods and compounds for treating diabetes | |
JP6033433B2 (en) | Method for treating hyperglycemia disorder using apolipoprotein AIV | |
US20230120635A1 (en) | Peptides and Fragments for Treating Diabetes and Associated Metabolic Diseases | |
US20220111011A1 (en) | Method and Compounds for Treating Diabetes and Associated Metabolic Diseases | |
TW200906433A (en) | Therapeutic agent for acute hepatitis or prophylactic and/or therapeutic agent for fulminant hepatitis | |
RU2280468C2 (en) | Composition for prophylaxis and treatment of obesity | |
CN107050429B (en) | Application of human fibroblast growth factor 21 in preparing medicine for treating cerebral apoplexy | |
CN111500636B (en) | Virus vector for treating autoimmune related diseases and construction method and application thereof | |
TW201601729A (en) | Pdia4 protein as a target for diagnosis, monitoring and treatment of diabetes | |
CN105348380B (en) | Dog fibroblast growth factor 21 and its purposes in treatment dog endocrine system disease | |
CN111574590B (en) | Polypeptide with anti-tumor function and application thereof | |
CN116615224A (en) | Methods and compounds for treating diabetes and related metabolic disorders | |
CN113476591B (en) | Application of milk-derived polypeptide derivative in preparation of diabetes prevention and treatment drugs, health care products and food additives | |
CN102370985A (en) | Purpose of agonist of natriuretic peptide receptor A in pain management | |
WO2023217267A1 (en) | Nucleic acid construct comprising utr and use thereof | |
US20160058844A1 (en) | "Bilirubin Excretion Enhancer" | |
TW201808987A (en) | GM-CSF variants and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18936064 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18936064 Country of ref document: EP Kind code of ref document: A1 |